DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)

South Korea flag South Korea · Delayed Price · Currency is KRW
25,600
-2,900 (-10.18%)
Apr 10, 2026, 3:30 PM KST
Market Cap1.15T +74.3%
Revenue (ttm)926.88B +14.1%
Net Income66.02B +7.8%
EPS1,475.00 +7.8%
Shares Out45.11M
PE Ratio17.36
Forward PE13.59
Dividend200.00 (0.70%)
Ex-Dividend DateDec 29, 2025
Volume2,113,224
Average Volume1,045,043
Open26,800
Previous Close28,500
Day's Range24,850 - 26,800
52-Week Range14,470 - 31,250
Beta0.09
RSI56.95
Earnings DateMay 15, 2026

About DongKook Pharmaceutical

DongKook Pharmaceutical Co., Ltd. produces and sells pharmaceutical products in South Korea and internationally. The company offers non-prescription and prescription drugs, quasi drugs, medical devices, active pharmaceutical ingredients, cosmetics, and other products. Its pipeline includes DKF-MB601, used to treat Hepatitis B; DKF-MB501, to treat obesity; DKM-412 and DKM-420 to treat osteoarthritis; DKF-313, indicated for benign prostatic hyperplasia; DKF-447, to treat diabetes; DKB-123, used for wound healing, tissue repair; and DKM-428, used ... [Read more]

Sector Healthcare
Founded 1968
Employees 1,233
Stock Exchange KOSDAQ
Ticker Symbol 086450
Full Company Profile

Financial Performance

In 2025, DongKook Pharmaceutical's revenue was 926.88 billion, an increase of 14.12% compared to the previous year's 812.17 billion. Earnings were 66.02 billion, an increase of 8.64%.

Financial Statements